Target intelligence / Profile preview

Voltage-gated calcium channel α1–β interface (CaVα1:CaVβ interface)

Target
CaVα1:CaVβ interface
Molecular classification
Ion channel, Voltage-gated calcium channel (VGCC) subunit interface, Protein–protein interaction site
01

Overview

The **Voltage-gated calcium channel α1–β interface** (CaVα1:CaVβ interface) is a specific molecular interaction between the main pore-forming α1 subunit and the auxiliary β subunit found in high-voltage-activated voltage-gated calcium channels (VGCCs), especially CaV1 (L-type) and CaV2 (N- and P/Q-type) channels[1][2][4][5][6]. This interface is critical for the biogenesis, trafficking, and gating properties of these channels. The α1 subunit (e.g., Cav1.2 or Cav2.2) determines ion selectivity and voltage sensitivity, while the β subunit modulates channel gating, enhances trafficking to the plasma membrane, and stabilizes open conformations. Disruption of this interface reduces channel expression and activity, making it a potential target for novel therapeutics (especially those aiming to dampen excessive calcium influx in diseases like cardiac arrhythmia and neuropathic pain)[1][5][6]. Many clinically used drugs target the α1 subunit; emerging compounds and research focus on the α1–β interface as a site for allosteric modulation.

Other names
CaV channel α1–β interfaceCaV1/CaV2 α1–β interaction siteCaV channel auxiliary subunit interface
02

Mechanism of action

Inhibition of channel activity by stabilizing the inactivated state (drugs like dihydropyridines) Disruption of α1–β subunit interaction can reduce channel trafficking to the membrane and reduce channel activity

03

Biological functions

Signal transductionExcitation–contraction couplingNeurotransmitter releaseRegulation of gene expressionSynaptic transmission
04

Disease associations

Cardiovascular diseaseNeurodegenerative diseaseArrhythmiaHypertensionPsychiatric disorders (indirectly via CaV channel function)
05

Safety considerations

Cardiac arrhythmia (QT prolongation)HypotensionNegative inotropyNeuronal dysfunction (when broadly inhibiting CaV1/CaV2 channels)
06

Interacting drugs

Dihydropyridines (e.g., nifedipine, amlodipine) [on CaV1.2 channel]

4 more in the full profile.

07

Biomarkers

CACNA1C or CACNA1A gene expression (for CaV1.2 and CaV2.1 channel activity)CaVβ subunit expressionL-type calcium channel functional assays (indirect)

Beyond the preview

Go deeper on Voltage-gated calcium channel α1–β interface (CaVα1:CaVβ interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voltage-gated calcium channel α1–β interface (CaVα1:CaVβ interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call